Financials data is unavailable for this security.
View more
Year on year Hinova Pharmaceuticals Inc had revenues fall -100.00% from 1.65m to 0.00, though the company grew net income from a loss of 301.51m to a smaller loss of 294.16m.
Gross margin | -400.96% |
---|---|
Net profit margin | -209,012.60% |
Operating margin | -208,997.50% |
Return on assets | -14.92% |
---|---|
Return on equity | -16.75% |
Return on investment | -16.50% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Hinova Pharmaceuticals Inc fell by 388.38m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 255.51m for operations while cash used for investing totalled 99.33m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 12.92 |
---|---|
Tangible book value per share | 12.61 |
More ▼
Balance sheet in CNYView more
Current ratio | 7.21 |
---|---|
Quick ratio | 7.21 |
Total debt/total equity | 0.0374 |
---|---|
Total debt/total capital | 0.036 |
More ▼